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Objective: Mutations in the X-chromosomal PLS3-gene, encoding Plastin 3, lead to
severe early-onset osteoporosis, suggesting a major role for PLS3 in bone metabolism.
However, the consequences of abnormal PLS3 function in bone and other tissues remain
incompletely characterized. This study evaluated spinal consequences of aberrant PLS3
function in patients with PLS3 mutations.
Design: A cross-sectional cohort study with spinal magnetic resonance imaging of 15
PLS3 mutation-positive (age range 9–77 years) and 13 mutation-negative (9–70 years)
subjects. Images were reviewed for spinal alignment, vertebral heights and morphology,
intervertebral disc changes and possible endplate deterioration.
Results: Vertebral changes were significantly more prevalent in the mutation-positive
subjects compared with the mutation-negative subjects; they were most abundant in
upper thoracic spine, and in all age groups and both sexes, although more prominent
in males. Difference in anterior vertebral height reduction was most significant in T5
and T6 (p = 0.046 and p = 0.041, respectively). Mid-vertebral height reduction was
most significant in T3 and T5 (p = 0.037 and p = 0.005, respectively), and, for
male mutation-positive subjects only, in T4 and T6–10 (p = 0.005–0.030 for each
vertebra). Most of the abnormal vertebrae were biconcave in shape but thoracic kyphosis
or lumbar lordosis were unchanged. Vertebral endplates were well-preserved in the
mutation-positive subjects with even fewer Schmorl nodes than the mutation-negative
subjects (10 vs. 16).
Conclusions: Compromised PLS3 function introduces severe and progressive changes
to spinal structures that are present already in childhood, in both sexes and most
abundant in upper thoracic spine. Cartilaginous structures are well-preserved.
Keywords: PLS3, magnetic resonance imaging, vertebral compression fracture, schmorl node, intervertebral disc
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INTRODUCTION
Compromised bone strength predisposes to vertebral
compression fractures (VCFs) and changes in spinal alignment.
VCFs are the most common complication of osteoporosis
and spinal pathology a primary finding in different forms
of bone fragility disorders, such as osteogenesis imperfecta
(OI), occurring in up to 78% of OI patients (1). Due to
skeletal fragility and ligamentous laxity, OI patients also
suffer from other spinal changes, such as kyphosis, scoliosis,
basilar impression and lumbosacral pathology (2). VCFs and
other spinal abnormalities are linked to the disease severity
and age of onset and can be greatly debilitating, resulting in
severe disfigurement, chronic pain and decreased quality of
life (3).
PLS3 osteoporosis was first described in 2013 as mutations
in the X-chromosomal PLS3, encoding Plastin 3 (PLS3), were
recognized to lead to severe childhood-onset osteoporosis (4).
Since then, many families worldwide have been reported with
variable forms of PLS3-related skeletal fragility (5–8). Due
to its X-chromosomal inheritance pattern, hemizygous males
are typically more severely affected than heterozygous females,
portraying markedly decreased bone mineral density (BMD) and
multiple peripheral and VCFs starting from an early age (5, 6).
Heterozygous females present with a variable phenotype ranging
from normal to skeletal fragility with few or multiple fractures
(5, 6, 8). Bone tissue is characterized by low bone turnover with
reduced osteoblast and osteoclast numbers and disturbed matrix
mineralization (6, 7, 9).
PLS3 is thought to function as a modulator of intracellular
cytoskeletal organization and actin bundling, thus partaking in
various cellular functions such as cell migration and adhesion
(10). In bone, PLS3 is proposed to regulate osteocyte function,
their mechanosensing properties and matrix mineralization
(7), while studies on Pls3 knock-out (KO) mice also point
to an osteoclast-regulatory role (11). However, the exact
pathomechanisms of impaired PLS3 function in bone are
still unknown and hence the skeletal features, natural
course and optimal treatment of PLS3 osteoporosis remain
incompletely characterized. Furthermore, although no extra-
skeletal manifestations are evident in humans or in Pls3-KO
mice, the importance of PLS3 in other tissues remains elusive
(4, 5, 11).
To date, we have identified four unrelated Finnish families
with PLS3 osteoporosis due to different PLS3 mutations (5,
8, 12). Granted the access to this unique cohort of PLS3
mutation-positive subjects, we set out to evaluate their spinal
pathology using magnetic resonance imaging (MRI). Deduced
from observed VCFs in plain radiographs, thoracic kyphosis
and anamnestic loss of adult height (5), we hypothesized that
spinal changes are a particular feature of PLS3 osteoporosis
and that their age of onset, severity and location might differ
from that of other forms of osteoporosis (13, 14). Specifically,
we evaluated the number, location and severity of affected
vertebrae, abnormalities in spinal stature and possible changes
in cartilaginous tissues. Our findings on 15 mutation-positive
subjects indicate that impaired PLS3 function causes significant




We have previously identified four unrelated Finnish families
with PLS3 osteoporosis due to different PLS3 mutations
(Figure 1) (5, 8, 12). Family A has an intronic PLS3 splice
site mutation c.73–24T>A (p.Asp25Alafs∗17) as previously
described (5). Family B has a 12.5 kb tandem duplication
spanning intron 2 to 3 of PLS3, identified by array-comparative
genomic hybridization and predicted to lead to loss of function
(12). Family C includes a single subject with a de novo
heterozygous missense mutation c.1424A>G (p.Asn446Ser),
identified through Sanger sequencing of the whole gene
(8). Lastly, Family D has a nonsense mutation c.766C>T
(p.Arg256∗), also found by Sanger sequencing (8). In addition
to these identified individuals, we have offered genetic testing
to relatives at risk and as a result, to date, altogether 21
PLS3 mutation-positive subjects have been identified in these
four families.
For the current study, we offered all mutation-positive
subjects (n= 20, one deceased) the opportunity to participate in a
study concerning spinal health in PLS3 osteoporosis. Altogether
15 mutation-positive subjects complied. To form a comparable
control group, we offered participation to also mutation-negative
family members (n= 18) and of them, 13 individuals consented.
In addition, we used previously obtained spinal MR-images of a
WNT1 mutation-positive subject for comparison; these images
were originally obtained for our analysis of WNT1-associated
spinal pathology (14). All subjects or their guardians gave a
written informed consent upon participation in the study. The
research protocol was approved by the Research Ethics Board of
Helsinki University Hospital.
Genetic Evaluations
We performed genetic validations on DNA extracted from
peripheral blood, as previously described (5, 8, 12). We screened
all samples for the families’ pertinent, previously identified PLS3
mutation (NCBI Reference Sequence NM_005032).
Clinical Cohort Characteristics
Altogether 11/15 of the mutation-positive subjects were clinically
evaluated during a study visit at Helsinki University Hospital for
clinical features, including anthropometry, spinal alignment and
spinal abnormalities. For all subjects, data on sustained fractures
and previous medical and surgical treatments were collected by
patient interviews and from prior medical records.
Magnetic Resonance Imaging
MR-imaging of the thoracic and lumbar spine were performed
in 2018 at different medical healthcare providers in Finland.
All images were obtained with one of three different 1.5-
T MRI scanners (Optima MR360 and Signa HDxt; General
Electric Healthcare, and MAGNETOM ESSENZA; Siemens
Healthcare) using a spine coil. The imaging sequences were
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FIGURE 1 | Pedigrees of the four included Finnish families with PLS3 mutations; (A) intronic splice site mutation c.73–24T>A (p.Asp25Alafs*17) (B), intragenic
tandem duplication within PLS3 (C), de novo heterozygous missense mutation c. 1424A>G (p.Asn446Ser) (D), non-sense mutation c.766C>T (p.Arg256*). The
pedigrees have been modified to ensure anonymity. Squares represent males, circles females.
selected from clinical protocols including T1-weighted sagittal
images (TR/TE 470–800/10–11ms, FOV 280–330mm, in-plane
resolution 0.6–0.9 × 0.6–0.9mm, slice thickness 3–4mm) and
T2-weighted sagittal images (TR/TE 2,600–3,500/80–98ms, FOV
280–330mm, in-plane resolution 0.6–0.9 x 0.6–0.9mm, slice
thickness 3–5mm) and T2-weighted fat-saturated inversion
recovery images (TR/TI/TE 3,000–3,200/130–160/47–67, FOV
310–320mm, in-plane resolution 1.3–1.4 × 1.3–1.4mm, slice
thickness 3–4mm) of lumbar and thoracic spine. All images were
obtained in supine position with the subject lying down, legs
extended horizontally.
TheMRIs were first independently assessed for spinal changes
by an orthopedic surgeon and three experienced radiologists
who were blinded to the subjects’ genotype and phenotype.
Statistical calculations for the vertebral measurements were made
from median values of two of the reviewers’ (MSP and STS)
independent calculations. The final conclusions were evaluated
for discrepancy by calculating Intraclass Correlation Coefficient
(ICC) for 10 randomly selected cases; for all the cases the ICC
score was >0.80 and therefore the analyses were considered
highly consistent and reproducible. The MRI data were assessed
as described later. Detailed methods for measuring these listed
parameters are available on request from the authors.
Vertebral Morphology
Changes were evaluated separately for each thoracic and lumbar
vertebral body (T1 to L4) using different clinically accepted
classification methods. To analyze the thoracic and lumbar
vertebral morphology, anterior, mid-vertebral and posterior
heights of the vertebrae as well as the anterior–posterior length
at the level of the basivertebral vein were measured. Vertebral
height loss was measured from ratios of anterior/posterior
and mid-vertebral/posterior heights. In addition, the ratio of
mid-vertebral height to anterior–posterior length (mid-vertebral
height/depth ratio) was assessed. We used a previously described
classification system for descriptive assessment of vertebral
morphology (15). The method classifies vertebral changes in
three subgroups according to type of deformity: grade 1 for
normal variation, grade 2 for anterior wedging (anterior height
reduction a ≥20 or b ≥50%), and grade 3 for compression
deformity (mid-vertebral height reduction a ≥20 or b ≥30%)
(15). The measures of mid-vertebral height/depth ratios were
compared between the mutation-positive and -negative groups.
Endplates
The number, location and extent of Schmorl nodes (SN) were
recorded using a modified classification system introduced by
Samartzis et al. (16). The recorded domains for each SN were
vertebrae level (T4–L4), endplate involvement (rostral, caudal, or
both) and size (<1/3, <2/3, or >2/3 of endplate).
Intervertebral Discs
Changes in the intervertebral discs were assessed by measuring
the total surface areas of the intervertebral discs from L3 to L5
and visually from images.
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TABLE 1 | History of fractures and previous osteoporosis medication for 15 subjects with a hemizygous/heterozygous PLS3 mutation and 13 mutation-negative subjects.













Number Age at 1st fracture (years)
Mutation-positive subjects: 15 subjects, 10 females/5 males, age range 9–77 years, median 42 years
Mutation-negative subjects: 13 subjects, 6 females/7 males, age range 9–70 years, median 40 years
Mutation-positive subjects
MP1 M 2 0–11 None 2 5 No No N/A
MP2 F 1 12–20 None – – No N/A N/A
MP3 F 3 12–20 PAM 2013,
ZOL 2014–
5 2 Yes Yes N/A
MP4 F 1 12–20 None – – No N/A N/A
MP5 F 1 12–20 None – – No No N/A
MP6 M 2 21–40 ZOL 2007–2009 1 17 Yes No N/A
MP7 M 4 21–40 None 4 10 Yes Yes N/A
MP8 F 1 41–60 ZOL 2016– – – No Yes No
MP9 F 2 41–60 None – – No Yes 1 cm
MP10 M 1 41–60 ZOL −2011 10 21 Yes Yes 3 cm
MP11 F 1 41–60 None – – No N/A N/A
MP12 F 1 41–60 PTH 2011–2013 – – Yes No No
MP13 F 4 41–60 None 1 35 No No 2 cm
MP14 F 1 61–80 PTH 2007–2008
ZOL 2010–2014
>10 5 Yes Yes 5 cm
MP15 M 1 61–80 ZOL 4 years 4 55 Yes Yes 11 cm
Mutation-negative subjects
MN1 M None 0–11 None 1 6 No N/A N/A
MN2 M None 0–11 None – – No N/A N/A
MN3 F None 12–20 None 1 9 No N/A N/A
MN4 M None 12–20 None – – No N/A N/A
MN5 F None 12–20 None 1 2 No N/A N/A
MN6 F None 21–40 None 2 16 No N/A N/A
MN7 F None 21–40 None 8 1 No N/A N/A
MN8 M None 41–60 None 2 16 No No N
MN9 M None 41–60 DMAB 2 years 3 30 Yes Yes N
MN10 M None 41–60 None 1 17 No N/A N/A
MN11 F None 41–60 None 1 8 No Yes N
MN12 F None 61–80 None 2 59 No N/A N/A
MN13 M None 61–80 ALN 2002–2007 – – Yes N/A 3 cm
PAM, pamidronate; ZOL, zoledronic acid; PTH teriparatide; DMAB, denosumab; ALN, alendronate. F, female; M, male; N/A, data not available; VCF, vertebral compression fracture.
PLS3 mutations: 1. heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17); 2. heterozygous/hemizygous duplication spanning intron 2 to 3; 3. heterozygous missense
mutation c.1424A>G (p.Asn446Ser); 4. heterozygous/hemizygous nonsense mutation c.766C>T (p.Arg256* ).
Spinal Alignment
Changes in spinal stature were evaluated by calculating degrees
for thoracic kyphosis and lumbar lordosis. The angles were
calculated using a modified Cobb’s method by drawing tangent
lines to selected vertebral bodies (T1 and T12 for thoracic spine
and L1 and L5 for lumbar spine) (17). Median values were used
to compare differences between the two groups.
Statistical Analysis
Descriptive data are reported as median and range. Normality
of the data was assessed using Kolmogorov–Smirnov and
Shapiro–Wilk and visually using histograms. Mann–Whitney
U-test was used as appropriate (SPSS Statistics 25; IBM





The 15 PLS3 mutation-positive subjects (10 females, 5 males)
ranged in age from 9 to 77 years (median 42 years) (Figure 1,
Table 1). Altogether eight (53%) of them had sustained at least
one previous long-bone fracture and seven (47%) at least one
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FIGURE 2 | Representative spinal magnetic resonance images of thoracic and lumbar spines of four PLS3 mutation-positive subjects. (A) 9-year-old male, (B)
46-year-old male, (C) 77-year-old male, and (D) 70-year-old female. Images show mild vertebral changes in childhood (solid arrow), multiple and severe vertebral
compression fractures and kyphosis in early adulthood (dotted arrows), progression of spinal changes with increasing age. (D) portrays vertebral changes in
heterozygous females and a vertebral hemangioma (asterisk). Subject in (A) harbors an intragenic tandem duplication within PLS3, and subjects in (B–D) a
heterozygous/hemizygous PLS3 deletion c.73–24T>A (p.Asp25Alafs*17). (E) Shows thoracic and lumbar spine images of a 74-year-old female with WNT1
osteoporosis due to a heterozygous WNT1 mutation p.Cys218Gly, portraying the differences between PLS3 and WNT1 osteoporosis in type and location of vertebral
compression fractures, changes in spinal stature and presence of simultaneous deterioration in cartilaginous tissues. The images have been combined from separate
MR-images of thoracic and lumbar spines.
VCF. Seven subjects (47%) reported back pain; three of them
considered the pain disabling. Two of the nine adults reported
height loss of ≥4 cm. Seven subjects had received osteoporosis
medication prior to the study and for two of them, the treatment
was still ongoing at the time of the study (Table 1).
Mutation-Negative Subjects
The 13 PLS3 mutation-negative subjects (6 females, 7 males)
ranged in age from 9 to 70 years (median 40 years) (Figure 1,
Table 1). Altogether 10 (71%) of them had sustained one or more
previous peripheral fractures, two had previously been diagnosed
with compression fractures, two had mild back pain and none
reported a ≥4 cm height loss. Two had received osteoporosis
medications prior to the study.
MRI Findings
Vertebrae
Vertebral changes were significantly more frequent in the
mutation-positive subjects compared with the mutation-negative
subjects. They were present already in children and increasingly
prevalent with age. These vertebral changes were most abundant
and marked in the upper thoracic spine, specifically in T3–
T8 (Figures 2–4, Table 2). Loss of anterior vertebral height was
most significant in T5 and T6 in all mutation-positive subjects
compared with mutation-negative subjects (p = 0.046 and p
= 0.041, respectively) (Figure 3). For male subjects only, the
difference was significant in T5–T8 (p = 0.030 for T5 and p =
0.010 for others). In females, corresponding differences did not
reach statistical significance. Loss of mid-vertebral height was
most significant in T10 (p = 0.004) for all mutation-positive
subjects but for male subjects, the difference was significant in
T4 and T6–T10 (p = 0.030, p = 0.018, p = 0.003, p = 0.010, p
= 0.010, and p = 0.005, respectively) (Figure 4). In females, the
difference was significant in T12 (p = 0.031). When comparing
the ratio of mid-vertebral height to anterior–posterior length,
the difference between all the mutation-positive and -negative
subjects was significant in T3 and T5 (p = 0.037 and p = 0.005,
respectively) (Figure 4). For male subjects alone, the difference
was significant in T5, T7, and T8 (p = 0.018, p = 0.030, and p =
0.018, respectively), and in females, the difference was significant
in T5 (p = 0.016) (Figure 4). Significant differences persisted
when results were compared in only subjects under the age of 30
years: decrease in anterior height was significant in T6 (p= 0.022)
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FIGURE 3 | Comparison of anterior vertebral height reduction in 15 PLS3 mutation-positive and 13 mutation-negative subjects. Ratios of anterior to posterior
vertebral height in (A) T5, (B) T6, (C) T7, (D) T8, (E) T5, and (F) T6. MP = mutation-positive, MN, mutation-negative; M, male; F, female. The PLS3 mutation-positive
subjects harbor different mutations: nine with heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with heterozygous/hemizygous intragenic
tandem duplication within PLS3, one with heterozygous missense mutation c.1424A>G (p.Asn446Ser), and two with heterozygous/hemizygous non-sense mutation
c.766C>T (p.Arg256*). *p < 0.05.
and decrease in mid-vertebral height in T10 (p = 0.002). In the
mutation-positive subjects, most of the abnormal vertebrae were
both reduced in height and biconcave in shape and graded as 3a
according to theMäkitie et al. vertebral morphology classification
(Figure 5). None of the abnormal vertebrae protruded into the
spinal canal or caused evident spinal stenosis.
Overall appearance of the vertebrae was similar in both
mutation-positive and -negative subjects. Isolated findings of
heterogenous coloring or intravertebral adiposity were noted.
One female subject (MP14) had one large hemangioma in L4
(Figure 2).
Vertebral Endplates
For both mutation-positive and -negative subjects, SNs were
most prevalent in the lower thoracic and lumbar spine. Both
groups had both rostral and caudal SNs and the total number
was similar in both groups [5/15 (33%) vs. 4/13 (31%)]. The range
and total number of all SNs was higher in the mutation-negative
subjects: 1–2 vs. 1–10 and 10 vs. 16, respectively (Figure 6).
Intervertebral Discs
Although vertebral height reduction was significant and the
vertebrae most often biconcave in shape in the mutation-positive
subjects, no obvious changes were observed in the intervertebral
discs. Median surface areas of the intervertebral discs from L3 to
L5 were 913 and 933 mm2 (p= 0.943). Some intervertebral discs
were enlarged and balloon-shaped secondary to the biconcavity
of the abnormal shape of vertebrae (Figures 2B–D).
Spinal Alignment
VCFs caused changes in the mutation-positive subjects’ spinal
alignment that was most often visually evident as a notch
in the upper thoracic spine. Although abnormal vertebrae
were prevalent in the mutation-positive subjects, secondary
enlargement of intervertebral discs tended to maintain the spinal
alignment. Thus, the overall degree of thoracic kyphosis was
similar when calculated with the Cobb’s method: 28 vs. 33◦ for the
mutation-positive and -negative subjects, respectively (p= 0.950)
(Figure 7). Due to the thoracic notch, the degree of lordosis was
decreased, and the lumbar spines appeared straighter than in the
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FIGURE 4 | Comparison of ratios of mid-vertebral to posterior vertebral height (A–D) and mid-vertebral height to anterior–posterior length (E–H) in 15 PLS3
mutation-positive and 13 mutation-negative subjects. Ratios of mid-vertebral to posterior vertebral height in (A) T7, (B) T8, (C) T9, and (D) T10 and ratios of
mid-vertebral height to anterior–posterior length in (E) T3, (F) T5, (G) T7, and (H) T8. MP, mutation-positive, MN, mutation-negative, M, male, F, female. The PLS3
mutation-positive subjects harbor different mutations: nine with heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with
heterozygous/hemizygous intragenic tandem duplication within PLS3, one with heterozygous missense mutation c.1424A>G (p.Asn446Ser), and two with
heterozygous/hemizygous nonsense mutation c.766C>T (p.Arg256*). *p < 0.05.
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Anterior–posterior height ratio Mid-vertebral–posterior height ratio Mid-vertebral height–AP-length ratio
Th1 0.717 0.005 1.000 0.428 0.339 −0.018 0.432 0.792 0.235 −0.061 1.000 0.220
Th2 0.052 0.021 0.639 0.220 1.000 −0.005 0.755 0.792 0.156 −0.067 0.639 0.056
Th3 0.892 −0.011 0.343 0.792 0.185 −0.048 0.530 0.313 0.037 −0.102 0.106 0.093
Th4 0.964 −0.002 0.149 0.875 0.065 −0.048 0.030 0.635 0.065 −0.057 0.073 0.220
Th5 0.046 −0.044 0.030 0.147 0.058 −0.062 0.149 0.147 0.005 −0.165 0.018 0.016
Th6 0.041 −0.054 0.010 0.147 0.130 −0.051 0.018 0.313 0.108 −0.094 0.073 0.056
Th7 0.080 −0.069 0.010 0.713 0.274 −0.084 0.003 0.562 0.185 −0.101 0.030 0.492
Th8 0.413 −0.030 0.010 0.635 0.118 −0.080 0.010 0.713 0.170 −0.071 0.018 0.428
Th9 0.294 −0.052 0.432 0.220 0.142 −0.063 0.010 0.635 0.525 −0.050 0.149 0.958
Th10 0.856 0.015 0.530 0.635 0.004 −0.086 0.005 0.056 0.413 −0.057 0.202 0.713
Th11 1.000 −0.010 0.202 0.220 0.413 −0.040 0.876 0.492 0.892 −0.039 1.000 0.492
Th12 0.525 0.036 0.073 0.635 0.080 −0.036 1.000 0.031 0.201 −0.048 0.755 0.118
L1 1.000 −0.003 0.755 0.635 0.440 −0.042 0.432 0.313 0.413 −0.055 0.876 0.220
L2 0.440 0.027 1.000 0.428 0.964 −0.019 0.343 0.492 0.586 −0.086 0.876 0.147
L3 0.856 −0.023 0.876 0.368 0.892 −0.012 0.876 1.000 0.170 −0.044 0.432 0.056
L4 0.235 −0.027 0.149 0.562 1.000 −0.026 0.202 0.492 0.316 −0.046 0.432 0.263
p-values calculated with Mann–Whitney U test; values < 0.05 considered significant and marked in bold. The 15 mutation-positive subjects harbor different PLS3 mutations: nine with a
heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with heterozygous/hemizygous intragenic tandem duplication within PLS3, one with heterozygous missense
mutation c.1424A>G (p.Asn446Ser), and two with heterozygous/hemizygous nonsense mutation c.766C>T (p.Arg256*). Th, thoracic vertebra; L, lumbar vertebra; AP, anterior–posterior;
MP, mutation-positive; MN, mutation-negative; M, male; F, female.
mutation-negative subjects. The change in lumbar lordosis was
more pronounced than change in kyphosis, although statistically
not significant; the medians for lordosis were 37 vs. 30◦ for the
mutation-positive and -negative subjects (p= 0.520) (Figure 7).
DISCUSSION
This study is the first to report a systematic review of spinal
MRI findings in a large cohort of patients with defective PLS3
function. We assessed the spine in 15 mutation-positive subjects
with different PLS3mutations in four unrelated Finnish families.
Results were compared with congruent findings in 13 mutation-
negative individuals from the same families. We have previously
described that mutations in the X-chromosomally inherited PLS3
lead to a skeletal disorder predominantly in males characterized
by compromised bone strength, low rate of bone formation,
defective mineralization, and consequently prevalent fractures
and loss of adult height (5, 8, 12). Findings in the present
study indicate that defective PLS3 function leads to severe age-
and sex-related abnormalities in vertebral morphology already
in early childhood and to significant spinal pathology by early
adulthood. In contrast, spinal cartilaginous structures show no
premature deterioration.
The changes in vertebrae were significantly more severe
and prevalent in our cohort of PLS3 mutation-positive subjects
compared with the mutation-negative subjects. Despite the
relatively small number of subjects, reductions in anterior or
mid-vertebral heights were significantly greater as compared
with mutation-negative subjects, and most common in upper
thoracic vertebrae (T3–T8). These changes were also prevalent
even in children and young adults; significant anterior height
reduction was present in T6 and mid-vertebral height in T10
for subjects under 30 years of age. Although no longitudinal
data were available for individual subjects, the changes also
had an apparent progressive course with increasing age as
the older subjects presented with most widespread and severe
spinal deformities. When compared with mutation-negative
subjects, males were predominantly more severely affected
with a greater difference in mid-vertebral height reduction,
specifically in T4 and T6–T10. Though an anticipated sex
difference was seen, the females also had marked vertebral
Frontiers in Endocrinology | www.frontiersin.org 8 June 2020 | Volume 11 | Article 393
Mäkitie et al. PLS3 and the Spine
FIGURE 5 | Classification of abnormal vertebrae in (A) 15 PLS3 mutation-positive and (B) 13 mutation-negative subjects. Each abnormal vertebra was classified
according to a classification system for descriptive assessment of vertebral morphology, introduced by Mäkitie et al. (15), according to type of deformity: grade 1 for
normal variation, grade 2 for anterior wedging (anterior height reduction a ≥20% or b ≥50%), and grade 3 for compression deformity (mid-vertebral height reduction a
≥20% or b ≥30%) (15). MP, mutation-positive; MN, mutation-negative The PLS3 mutation-positive subjects harbor different mutations: nine with
heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with heterozygous/hemizygous intragenic tandem duplication within PLS3, one with
heterozygous missense mutation c.1424A>G (p.Asn446Ser), and two with heterozygous/hemizygous non-sense mutation c.766C>T (p.Arg256*).
FIGURE 6 | Number and location of Schmorl nodes in (A) 15 PLS3 mutation-positive and (B) 13 mutation-negative subjects. The PLS3 mutation-positive subjects
harbor different mutations: nine with heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with heterozygous/hemizygous intragenic tandem
duplication within PLS3, one with heterozygous missense mutation c.1424A>G (p.Asn446Ser), and two with heterozygous/hemizygous nonsense mutation
c.766C>T (p.Arg256*).
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FIGURE 7 | Comparison of (A) thoracic kyphosis and (B) lumbar lordosis in 15 PLS3 mutation-positive and 13 mutation-negative subjects. Thoracic kyphosis was
measured from T1 to T12 and lumbar lordosis from L1 to L5. MP, mutation-positive; MN, mutation-negative; M, male, F, female. The PLS3 mutation-positive subjects
harbor different mutations: nine with heterozygous/hemizygous deletion c.73–24T>A (p.Asp25Alafs*17), three with heterozygous/hemizygous intragenic tandem
duplication within PLS3, one with heterozygous missense mutation c.1424A>G (p.Asn446Ser), and two with heterozygous/hemizygous non-sense mutation
c.766C>T (p.Arg256*).
changes, while the level of statistical significance was reached
only in T12. Morphological classification indicated that most
often the changes were compression deformities resulting in
vertebral biconcavity.
We have previously reported severe spinal pathology in a
cohort of subjects with another form of primary osteoporosis
caused by a heterozygous loss-of-function mutation in WNT1
(14). The 17 WNT1 mutation-positive subjects exhibited
prevalent VCFs predominantly in the lower thoracic spine,
consequently exaggerated thoracic kyphosis and loss of adult
height. No VCFs were apparent in children and only came
apparent after the age of 50 years and seemed to progress with
increasing age thereafter (14). In comparison, our current study
demonstrates that PLS3 mutations seem to introduce vertebral
changes that are different in shape and spinal location, appear
at a much younger age and show greater magnification with
increasing age (Figure 2).
In addition to skeletal changes, we evaluated possible
cartilaginous tissue deterioration. Although PLS3 is ubiquitously
expressed in several other tissues, no constant extra-skeletal
manifestations are associated with PLS3 osteoporosis (4, 5, 8,
18). Congruently, Pls3-KO mice exhibit no evident extra-skeletal
abnormalities (11). Complete absence of Pls3 in a zebrafishmodel
resulted in embryonic lethality (11, 19). Tsolis et al. reported high
expression of PLS3 in chondrocytes isolated from osteoarthritis
(OA) patients’ articular cartilage, proposing a role for PLS3 in
chondrocyte regulation, while chondrocyte maturation appeared
normal in Pls3-KO mice (11, 20). Besides these, no detailed data
on PLS3 function in chondrogenesis is available. On the other
hand, studies on spinal muscular atrophy have evidenced that
PLS3 partakes in formation of neuromuscular synapses and that
its overexpression can salvage axonal defects in a SMA mouse
model (18, 21). Individual PLS3 patients have been reported to
have muscle hypotonia (8), but no systematic review of muscle
involvement in PLS3 osteoporosis has been reported.
In the present study the spinal cartilaginous tissues were
assessed by evaluating defects in vertebral endplates and
intervertebral discs. The number of SNs was similar in both
groups and even slightly higher in the mutation-negative
subjects. Further, vertebral endplates were well-preserved despite
the grave vertebral deformities. SNs represent intravertebral
disc herniations arising from disc degeneration and weakened
vertebral bone and are present even in the healthy population
(22). In contrast, we have previously reported increased
prevalence of SNs, enlarged intervertebral discs and endplate
deterioration in WNT1 osteoporosis, which we hypothesized to
arise from aberrant WNT pathway activation and its consequent
impact on the coupled osteogenesis and chondrogenesis (14).
From those results, we deduced that spinal cartilaginous
deterioration is a distinct feature ofWNT1 osteoporosis and SNs,
since prevalent also in children, could possibly predict future
VCFs. In contrast, cartilaginous tissue deterioration does not
seem to be a typical characteristic of PLS3 osteoporosis and the
difference to WNT1 osteoporosis is evident when comparing
the spinal structures and stature in PLS3 and WNT1 mutation-
positive subjects (Figure 2). Interestingly, while the effect of the
WNT1 mutation seems to be harmful for cartilaginous tissues
in vertebral endplates, we have previously reported that WNT1
mutation-positive subjects show less age-related deterioration
in knee articular cartilage indicating that in articular cartilage
the effect of the WNT1 mutation could have protective and
preservative consequences instead (23). The impact of PLS3
mutations on articular cartilage outside the vertebral endplates
has not be systematically studied. In light of the previously
reported increase in PLS3 expression in OA patients’ articular
chondrocytes indicating a role for PLS3 in OA pathogenesis (20),
it could also be postulated that decreased PLS3 function, as in
the case of loss-of-function PLS3mutations, could have cartilage-
preserving effects.
Our study has some limitations, primarily concerning the
relatively small cohort size, slightly unequal sex and age
distribution in the study groups and the cross-sectional nature
of the study. Also, the use of multiple MR-imaging machines
and some subjects’ prior or on-going osteoporosis medication
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can be considered as confounding factors. The MR-images were
taken in supine position and compared against data taken in
standing position. Several studies have indicated that kyphosis
is decreased in supine vs. standing position (24) and hence
this study is likely to underestimate the degree of kyphosis or
lordosis. Also, the relatively small cohort size posed limitations
to statistical analyses and may have prevented us from observing
some relevant differences between the groups. Regardless of
these limitations, we consider our study setting to be unique
with the largest-to-date cohort and individuals from the same
families, blinded nature of examinations, and good inter-reader
reliability. We therefore consider our findings novel and of
great value given the rarity of PLS3 mutation-positive subjects
and the lack of knowledge of PLS3 function in bone and
its relative skeletal pathology. These offer novel and clinically
valuable information about the differences between various
forms of primary osteoporosis, providing tools for clinical
differential diagnosis.
We conclude that defective PLS3 function due to pathogenic
variants in PLS3 causes significant, early-onset and sex-related
pathology in the axial skeleton both in males and females.
Changes in vertebral shape and height, presence of vertebral
compression fractures and consequent alterations in spinal
alignment are prevalent already in childhood and become
increasingly more severe and numerous affecting multiple
vertebrae with age. Changes in spinal cartilaginous tissues are not
present. Timely diagnosis and intervention are key in alleviating
progression of these pathological changes and reducing pain,
physical limitations and impaired quality of life. Regardless
of the growing number of reported PLS3 mutation-positive
individuals and clinical data on PLS3-related bone diseases,
our current knowledge on the function of PLS3 in bone and
other tissues is limited and our current means of diagnosis
and treatment insufficient. Further studies in larger cohorts
are needed to attain added information and help generate
targeted treatments.
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